Dr. Oleksowicz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
234 Goodman St
Barrett Center
Cincinnati, OH 45219Phone+1 513-584-6928Fax+1 513-584-4281- Is this information wrong?
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1988 - 1989
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1982 - 1984
- Tufts University School of MedicineClass of 1982
Certifications & Licensure
- OH State Medical License 2003 - 2026
- NY State Medical License 1984 - 2025
- CT State Medical License 2013 - 2015
- MO State Medical License 2012 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 109 citationsThe high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.David F. McDermott, Su Chun Cheng, Sabina Signoretti, Kim Margolin, Joseph I. Clark, Jeffrey A. Sosman, Janice P. Dutcher, Theodore F. Logan, Brendan D. Curti, Marc S....> ;Clinical Cancer Research. 2015 Feb 1
- 25 citationsSecretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer†Leslie Oleksowicz, Yin Liu, R. Bruce Bracken, Krishnanath Gaitonde, Barbara Burke, Paul A. Succop, Linda Levin, Zhongyun Dong, Shan Lu> ;The Prostate. 2012 Jul 1
- 14 citationsVav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.Zhongyun Dong, Yin Liu, Linda Levin, Leslie Oleksowicz, Jiang Wang, Shan Lu> ;Oncology Reports. 2011 Jun 1
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Cincinnati Medical CenterCincinnati, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: